BRPI0619712A2 - dispositivo para a identificação de um paciente como um candidato para testes radiográficos para o cáncer do pulmão, composição para detectar radiograficamente um cáncer do pulmão de estágio adiantado, dispositivo para o ensaio do cáncer do pulmão, uso de um painel, e, dispositivo de diagnóstico para a detecção do cáncer do pulmão - Google Patents
dispositivo para a identificação de um paciente como um candidato para testes radiográficos para o cáncer do pulmão, composição para detectar radiograficamente um cáncer do pulmão de estágio adiantado, dispositivo para o ensaio do cáncer do pulmão, uso de um painel, e, dispositivo de diagnóstico para a detecção do cáncer do pulmão Download PDFInfo
- Publication number
- BRPI0619712A2 BRPI0619712A2 BRPI0619712-4A BRPI0619712A BRPI0619712A2 BR PI0619712 A2 BRPI0619712 A2 BR PI0619712A2 BR PI0619712 A BRPI0619712 A BR PI0619712A BR PI0619712 A2 BRPI0619712 A2 BR PI0619712A2
- Authority
- BR
- Brazil
- Prior art keywords
- lung cancer
- panel
- patient
- markers
- marker
- Prior art date
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 138
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 134
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 134
- 238000012360 testing method Methods 0.000 title claims abstract description 64
- 238000001514 detection method Methods 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000003556 assay Methods 0.000 title description 67
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 48
- 239000003550 marker Substances 0.000 claims description 56
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 26
- 239000008280 blood Substances 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 15
- 239000007790 solid phase Substances 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000002596 correlated effect Effects 0.000 claims description 4
- 230000000737 periodic effect Effects 0.000 claims description 2
- 238000002601 radiography Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 6
- 238000002405 diagnostic procedure Methods 0.000 abstract description 4
- 230000034994 death Effects 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 61
- 238000012216 screening Methods 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 47
- 102000004169 proteins and genes Human genes 0.000 description 45
- 238000000034 method Methods 0.000 description 36
- 238000002591 computed tomography Methods 0.000 description 31
- 238000003745 diagnosis Methods 0.000 description 27
- 229920001184 polypeptide Polymers 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 238000002493 microarray Methods 0.000 description 23
- 230000035945 sensitivity Effects 0.000 description 23
- 238000005259 measurement Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 13
- 239000013610 patient sample Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000036210 malignancy Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000010200 validation analysis Methods 0.000 description 11
- 239000012528 membrane Substances 0.000 description 10
- 206010054107 Nodule Diseases 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000012549 training Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 230000000391 smoking effect Effects 0.000 description 7
- 238000002820 assay format Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000007477 logistic regression Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000002600 positron emission tomography Methods 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102000018546 Paxillin Human genes 0.000 description 5
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 5
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 102100029907 Exocyst complex component 6B Human genes 0.000 description 4
- 101001011230 Homo sapiens Exocyst complex component 6B Proteins 0.000 description 4
- 208000000017 Solitary Pulmonary Nodule Diseases 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000011976 chest X-ray Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100040578 G antigen 7 Human genes 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000015335 Ku Autoantigen Human genes 0.000 description 2
- 108010025026 Ku Autoantigen Proteins 0.000 description 2
- 108091007767 MALAT1 Proteins 0.000 description 2
- 101100460147 Sarcophaga bullata NEMS gene Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000007435 diagnostic evaluation Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000012636 positron electron tomography Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100021897 Cyclin-P Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101000897443 Homo sapiens Cyclin-P Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 238000007727 cost benefit analysis Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005823 lung abnormality Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000012831 peritoneal equilibrium test Methods 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012877 positron emission topography Methods 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012954 risk control Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000013274 transthoracic needle biopsy Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73541805P | 2005-11-10 | 2005-11-10 | |
| US73555505P | 2005-11-10 | 2005-11-10 | |
| US60/735,418 | 2005-11-10 | ||
| US60/735,555 | 2005-11-10 | ||
| US80677806P | 2006-07-08 | 2006-07-08 | |
| US60/806,778 | 2006-07-08 | ||
| PCT/US2006/060796 WO2007079284A2 (en) | 2005-11-10 | 2006-11-10 | Lung cancer diagnostic assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0619712A2 true BRPI0619712A2 (pt) | 2011-10-11 |
Family
ID=38228904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0619712-4A BRPI0619712A2 (pt) | 2005-11-10 | 2006-11-10 | dispositivo para a identificação de um paciente como um candidato para testes radiográficos para o cáncer do pulmão, composição para detectar radiograficamente um cáncer do pulmão de estágio adiantado, dispositivo para o ensaio do cáncer do pulmão, uso de um painel, e, dispositivo de diagnóstico para a detecção do cáncer do pulmão |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20090197285A1 (enExample) |
| EP (1) | EP1952157A4 (enExample) |
| JP (1) | JP2009516178A (enExample) |
| KR (1) | KR20080073740A (enExample) |
| CN (1) | CN103245784A (enExample) |
| AU (1) | AU2006332597A1 (enExample) |
| BR (1) | BRPI0619712A2 (enExample) |
| CA (1) | CA2632190A1 (enExample) |
| WO (1) | WO2007079284A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2652043A1 (en) * | 2006-05-12 | 2007-11-22 | University Of Miami | Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma |
| KR101018665B1 (ko) | 2008-08-18 | 2011-03-04 | 재단법인서울대학교산학협력재단 | 전립선암 진단 방법 및 장치 |
| MX355020B (es) * | 2010-07-09 | 2018-04-02 | Somalogic Inc | Biomarcadores de cancer de pulmon y usos de los mismos. |
| JP5931874B2 (ja) | 2010-08-13 | 2016-06-08 | ソマロジック・インコーポレーテッド | 膵癌バイオマーカーおよびその使用 |
| EP2660597B1 (en) * | 2010-12-28 | 2017-09-13 | ARKRAY, Inc. | Method for determining condition of oral cavity and analytical tool, apparatus and program used for the method |
| EP2780714B1 (en) | 2011-11-15 | 2017-08-16 | University Of Miami | Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma |
| WO2016013400A1 (ja) * | 2014-07-24 | 2016-01-28 | 国立大学法人 長崎大学 | 肺癌診断用バイオマーカー |
| CN110579611B (zh) * | 2019-09-18 | 2023-01-31 | 郑州大学 | 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法 |
| US11760170B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Olfaction sensor preservation systems and methods |
| US11636870B2 (en) | 2020-08-20 | 2023-04-25 | Denso International America, Inc. | Smoking cessation systems and methods |
| US11932080B2 (en) | 2020-08-20 | 2024-03-19 | Denso International America, Inc. | Diagnostic and recirculation control systems and methods |
| US12269315B2 (en) | 2020-08-20 | 2025-04-08 | Denso International America, Inc. | Systems and methods for measuring and managing odor brought into rental vehicles |
| US12251991B2 (en) | 2020-08-20 | 2025-03-18 | Denso International America, Inc. | Humidity control for olfaction sensors |
| US11881093B2 (en) | 2020-08-20 | 2024-01-23 | Denso International America, Inc. | Systems and methods for identifying smoking in vehicles |
| US12377711B2 (en) | 2020-08-20 | 2025-08-05 | Denso International America, Inc. | Vehicle feature control systems and methods based on smoking |
| US11828210B2 (en) | 2020-08-20 | 2023-11-28 | Denso International America, Inc. | Diagnostic systems and methods of vehicles using olfaction |
| US11813926B2 (en) | 2020-08-20 | 2023-11-14 | Denso International America, Inc. | Binding agent and olfaction sensor |
| US12017506B2 (en) | 2020-08-20 | 2024-06-25 | Denso International America, Inc. | Passenger cabin air control systems and methods |
| US11760169B2 (en) | 2020-08-20 | 2023-09-19 | Denso International America, Inc. | Particulate control systems and methods for olfaction sensors |
| CN116312739A (zh) * | 2021-12-20 | 2023-06-23 | 博尔诚（北京）科技有限公司 | 基于甲基化测序的标志物筛选方法、癌症检测方法及装置 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351824A (en) * | 1981-02-05 | 1982-09-28 | Icl Scientific | Polystyrene latex reagents, methods of preparation, and use in immunological procedures |
| AU632469B2 (en) * | 1988-04-04 | 1993-01-07 | Johns Hopkins University, The | A method for early detection of lung cancer |
| CA2665707C (en) * | 1997-06-26 | 2013-02-12 | The Regents Of The University Of Michigan | Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum |
| GB9810040D0 (en) * | 1998-05-11 | 1998-07-08 | Univ Nottingham | Blood borne tumour markers |
| GB9827228D0 (en) * | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
| US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
| EP1259545A2 (en) * | 2000-01-21 | 2002-11-27 | Ludwig Institute For Cancer Research | Small cell lung cancer associated antigens and uses therefor |
| JP2001343389A (ja) * | 2000-03-30 | 2001-12-14 | Nippon Kayaku Co Ltd | Ｍｄｍ２に対する自己抗体の測定によるがんの検査方法およびその試薬 |
| CA2462216A1 (en) * | 2001-11-09 | 2003-08-07 | Benaroya Research Institute At Virginia Mason | Antigen panels and methods of using the same |
-
2006
- 2006-11-10 KR KR1020087013907A patent/KR20080073740A/ko not_active Withdrawn
- 2006-11-10 EP EP06849131A patent/EP1952157A4/en not_active Ceased
- 2006-11-10 US US12/093,082 patent/US20090197285A1/en not_active Abandoned
- 2006-11-10 CA CA002632190A patent/CA2632190A1/en not_active Abandoned
- 2006-11-10 CN CN2013100906331A patent/CN103245784A/zh active Pending
- 2006-11-10 WO PCT/US2006/060796 patent/WO2007079284A2/en not_active Ceased
- 2006-11-10 BR BRPI0619712-4A patent/BRPI0619712A2/pt not_active IP Right Cessation
- 2006-11-10 JP JP2008540361A patent/JP2009516178A/ja active Pending
- 2006-11-10 AU AU2006332597A patent/AU2006332597A1/en not_active Abandoned
-
2012
- 2012-03-26 US US13/430,474 patent/US20120231966A1/en not_active Abandoned
-
2013
- 2013-10-04 US US14/046,271 patent/US20140066329A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006332597A1 (en) | 2007-07-12 |
| CN103245784A (zh) | 2013-08-14 |
| US20140066329A1 (en) | 2014-03-06 |
| US20120231966A1 (en) | 2012-09-13 |
| US20090197285A1 (en) | 2009-08-06 |
| CA2632190A1 (en) | 2007-07-12 |
| KR20080073740A (ko) | 2008-08-11 |
| EP1952157A2 (en) | 2008-08-06 |
| EP1952157A4 (en) | 2009-04-08 |
| WO2007079284A3 (en) | 2008-09-18 |
| JP2009516178A (ja) | 2009-04-16 |
| WO2007079284A2 (en) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120231966A1 (en) | Lung cancer diagnostic assay | |
| US20100093108A1 (en) | Lung cancer diagnotic assay | |
| JP5591711B2 (ja) | 結腸直腸癌のためのマーカーパネル | |
| JP6026422B2 (ja) | 肺がん試験 | |
| US8216789B2 (en) | Diagnostic panel of cancer antibodies and methods for use | |
| Wang et al. | Evaluation of the clinical application of multiple tumor marker protein chip in the diagnostic of lung cancer | |
| CN109187979B (zh) | 蛋白芯片、蛋白质芯片诊断试剂盒制备及使用方法 | |
| CN106680515B (zh) | 用于肺癌诊断的多分子标志物组合 | |
| CN114167059B (zh) | 一种用于食管鳞癌诊断的生物标志物及检测试剂盒 | |
| CN109116023A (zh) | 一种肺癌标志物抗-mmp12自身抗体及其应用 | |
| CN113075413A (zh) | 基于一组肿瘤相关抗原的早期食管鳞癌筛查试剂盒 | |
| KR102131860B1 (ko) | 아르기닌이 메틸화된 ggt1에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물 | |
| US7611845B2 (en) | Serum levels of HER2/neu as an indicator of clinical state and prognosis of prostate cancer | |
| EP2619218B1 (en) | Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof | |
| CN116500267B (zh) | 一种用于afp阴性肝癌诊断的生物标志物及检测试剂盒 | |
| MX2008006130A (en) | Lung cancer diagnostic assay | |
| CN101374962A (zh) | 肺癌的诊断分析法 | |
| CN120214314A (zh) | Uchl1在制备预测hcc阿替利珠单抗联合贝伐珠单抗疗效和预后的检测产品中的用途 | |
| CN118777605A (zh) | 一种用于胰腺癌早期诊断的生物标志物及检验试剂盒 | |
| EP2963124B1 (en) | Biomarker combinations for use in pancreatic cancer screening |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |